EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...

COVID-19, influenza and RSV are the main threats between October and May. There are vaccines for all three viruses, so you ...

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

The Eastern Ontario Health Unit (EOHU) is pleased to announce that a new preventive treatment that protects against ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval by the 2025-2026 season.

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

The Eastern Ontario Health Unit is advising a new treatment is now available in the region to help protect infants from the ...

The company first reported that the Phase IIb/III MK-1654-004 trial (NCT04767373) evaluating clesrovimab as a preventative treatment for RSV in infants met its primary endpoint in July.

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...